Monoclonal Antibody Therapy
Anti-COVID-19 Monoclonal Antibody Information
- Monoclonal antibody therapy has been shown to reduce the risk of developing COVID-19 after an exposure, and to reduce the risk of hospitalization or death in high-risk individuals who are infected.
- Can be given either as an injection or infusion
- Not FDA approved, but rather has an Emergency Use Authorization for adults and children between ages 12-17 weighing over 40 kg (88 lb)
Who qualifies for Anti-COVID-19 Monoclonal Antibodies?
Due to the ongoing COVID surge there is a high demand for monoclonal antibodies nationwide and supply is currently limited. In accordance with National Institutes of Health guidelines, we are currently offering monoclonal antibody therapy only to those individuals who meet the following criteria:
If unvaccinated or incompletely vaccinated:
Individuals must have symptoms of COVID-19, have a positive COVID test result, be within 7 days of symptom onset and have a high-risk condition*. Persons hospitalized for COVID-19 or on supplemental oxygen are not candidates for monoclonal antibody therapy.
- ≥ 65 years of age
- Obesity (body mass index ≥35)
- Chronic kidney disease
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease or high blood pressure
- Chronic lung disease
- Sickle cell disease
- Neurodevelopmental disorders
- Tracheostomy, gastrostomy, or positive pressure ventilation (not for COVID)
If fully vaccinated:
In addition to the above criteria, fully vaccinated individuals must also satisfy one of the following:
- ≥70 years of age
- Moderate to severely immunocompromised state
What to Expect
- Call your Virginia Mason health care provider to discuss next steps if you believe you qualify for anti-COVID-19 monoclonal antibody treatment.
- Your care team will guide you through steps to determine your eligibility, provide pre-treatment counseling, and arrange for treatment.
- You will receive the medication either as an intravenous infusion or as 4 injections.
- The FDA requires that you be observed for 1 hour after you have received the medication.
- For additional information, please review the FDA patient fact sheet.